A Positions are available within different teams and descriptions of the type of work undertaken by these groups is provided below.
Please read more about the different positions we are recruiting for across Adaptive Immunity by clicking apply and going to our website. When you apply you will be able to select three preferences. We will accommodate your preference where possible.
Research group one: Immunoregulation
As an IP student in Biology Group 1 you will have the opportunity to work alongside multidisciplinary scientists on projects encompassing; the identification of novel drug targets, the validation of the biology of drug targets and the development of innovative assays to support a drug target. You will be trained by an individual supervisor who will support your development throughout the year and you will be based within an open-plan, state-of-the-art collaborative research lab, fully integrated in a team of world-leading immunologists and cell and molecular biologists.
Research group two: Myeloid Adaptive Communication
As an Industrial Placement student, the research you conduct will support an active drug discovery programme where you will be given the opportunity to be trained by experienced scientists in a variety of laboratory techniques. In addition to the standard cell and molecular biology techniques, we have access to many state of the art technologies such as CRISPR methods, Seahorse metabolic analysis and Aurora flow cytometers. Depending on your project you will be exposed to techniques such as primary leukocyte isolation and characterisation; flow cytometry, RT-PCR and Western Blot for the quantification and functional analysis of white blood cells; ELISA/MSD/Luminex for protein quantification; metabolic analysis of primary white blood cells; proliferation and apoptosis assays; cell culture and transfections; or protein knock out using CRISPR.
Research group three: Barrier Dysfunction and B Cell Biology
As an IP student in Biology Group three you will have the opportunity to work alongside multidisciplinary scientists on projects encompassing; the identification and validation of the biology of novel drug targets, and the development of innovative assays to support a drug target. You will be trained by an individual supervisor who will support your development throughout the year and you will be based within an open-plan, state-of-the-art collaborative research lab, fully integrated in a team of world-leading immunologists and cell and molecular biologists. In addition to an introductory training course covering the basics of drug discovery, you will have the opportunity to learn a number of lab techniques throughout the year such as: primary human cell and tissue isolation, cytokine & immune cell profiling through flow cytometry, ELISA and MSD, transcriptomic analysis of cells by qPCR, confocal and high content microscopy, microbiology and virology, and many others.
Research group four: Genomic Immunology
As an IP you will contribute to validation of targets from the 23andMe collaboration with a focus on restoring tissue homeostasis and immune system regulation. As well as pursuing functional genomics and genetic approaches for target validation using in silico analyses and gene editing methods. The successful candidate will need to have excellent interpersonal skills, being able to work effectively in a multidisciplinary team as well as independently under general supervision and to interact positively and effectively with collaborating scientists within GSK. Understanding of immunology, genomics and drug development is highly desirable. Within this group you will gain comprehensive experience in experimental design, execution, assay development and analysis.
Research group five: Experimental Quantitative Pharmacology (eQP)
As an IP student you will have the opportunity to work alongside multidisciplinary scientists on projects within any of the biology groups in the AI-RU and could include work on myeloid, T- and B- cells, cell:cell communication, and barrier dysfunction.
Based within our state-of-the-art collaborative research lab you may also have the opportunities to work in the dedicated animal facility. Working alongside our group you will be trained in a range of in vitro and ex vivo laboratory techniques used in modern drug discovery including cell isolation and culture, and molecular techniques such as ELISA and flow cytometry. Using these techniques to aid the validation of in vivo targets; investigate the action of novel compounds; gain in depth knowledge of and refine pre-clinical models; and assess in vivo biomarkers suitability as clinical endpoints for patients. You will be given the opportunity to plan and conduct experiments, draw conclusions and present important decision driving data in group and programme meetings developing a wide range of soft skills.
Research group six: Immuno-Epigenetics Placement Advert
We are looking for highly motivated Industrial Placement students to join us in the Immuno-Epigenetics research unit based at Stevenage for one year starting in September 2020. Our focus in this exciting and fast-moving field, is to target the function of the immune system through modulation of the proteins which read, write or erase the epigenetic code, in order to develop new medicines for immune mediated diseases.
You will be fully integrated into a team of highly motivated and talented scientists with an exceptional publication and drug discovery record, who work across drug discovery from the initial stages of target identification to early clinical development.
What does an Adaptive Immunity Research Unit industrial placement have to offer?
Adaptive Immunity relies on the coordination and expansion of specific adaptive immune cells. Immune memory follows the adaptive response, when mature adaptive cells, highly specific to the original pathogen, are retained for later use. The Adaptive Immunity Research Unit at GSK is positioned to optimise our opportunities in this exciting area of research. Additionally the team has access to unprecedented genetic resources through GSK’s collaboration with 23andMe, FinnGen and Open Targets combined with cell specific epigenetic datasets and functional genomic screens to identify pathogenic cell types, pathways and targets.
The group is made up of five large teams focused on different aspects of adaptive immunity from integration of genetic and functional genomic target validation approaches through to immuno-regulation, myeloid-adaptive cell communication, tissue and adaptive immune cell interactions and translational models.